1
|
Lu XX, Yuan LY, Liu KQ, Zhang QQ, Wang X, Jiang XS, Zhang JS, Zhao XL. [Comparison of induction protocols for VEN+AZA and HAG+AZA in single-center elderly acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi 2023; 44:767-769. [PMID: 38049322 PMCID: PMC10630569 DOI: 10.3760/cma.j.issn.0253-2727.2023.09.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Indexed: 12/06/2023]
Affiliation(s)
- X X Lu
- Department of Hematology, Oncology Center, Tianjin Union Medical Center of Nankai University, Tianjin 300121, China
| | - L Y Yuan
- School of Medicine, Nankai University, Tianjin 300071, China
| | - K Q Liu
- Institute of Hematology & Blood Disease, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Q Q Zhang
- Department of Hematology, Oncology Center, Tianjin Union Medical Center of Nankai University, Tianjin 300121, China
| | - X Wang
- Department of Hematology, Oncology Center, Tianjin Union Medical Center of Nankai University, Tianjin 300121, China
| | - X S Jiang
- Department of Hematology, Oncology Center, Tianjin Union Medical Center of Nankai University, Tianjin 300121, China
| | - J S Zhang
- Department of Hematology, Oncology Center, Tianjin Union Medical Center of Nankai University, Tianjin 300121, China
| | - X L Zhao
- Department of Hematology, Oncology Center, Tianjin Union Medical Center of Nankai University, Tianjin 300121, China
| |
Collapse
|
2
|
Yang MZ, Li L, Wei H, Liu BC, Liu KQ, Li DP, Zhang L, Yang RC, Mi YC, Wang JX, Wang Y. [Clinical and genetic characteristics of patients with newly diagnosed acute promyelocytic leukemia: a single-center retrospective of 790 cases]. Zhonghua Xue Ye Xue Za Zhi 2022; 43:336-341. [PMID: 35680634 PMCID: PMC9189486 DOI: 10.3760/cma.j.issn.0253-2727.2022.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/14/2021] [Indexed: 11/05/2022]
Abstract
Objective: To retrospectively analyze the data of Chinese patients with newly diagnosed acute promyelocytic leukemia (APL) to preliminarily discuss the clinical and cytogenetic characteristics. Methods: From February 2004 to June 2020, patients with newly diagnosed APL aged ≥ 15 years who were admitted to the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College were chosen. Clinical and laboratory features were retrospectively analyzed. Results: A total of 790 cases were included, with a male to female ratio of 1.22. The median age of the patients was 41 (15-76) years. Patients aged between 20 and 59 predominated, with 632 patients (80%) of 790 patients classified as low and intermediate risk and 158 patients (20%) of 790 patients classified as high risk. The white blood cell, platelet, and hemoglobin levels at diagnosis were 2.3 (0.1-176.1) ×10(9)/L, 29.5 (2.0-1220.8) ×10(9)/L, and 89 (15-169) g/L, respectively, and 4.8% of patients were complicated with psoriasis. The long-form type of PML-RARα was most commonly seen in APL, accounting for 58%. Both APTT extension (10.3%) and creatinine>14 mg/L (1%) are rarely seen in patients at diagnosis. Cytogenetics was performed in 715 patients with newly diagnosed APL. t (15;17) with additional chromosomal abnormalities were found in 155 patients, accounting for 21.7%; among which, +8 was most frequently seen. A complex karyotype was found in 64 (9.0%) patients. Next-generation sequencing was performed in 178 patients, and 113 mutated genes were discovered; 75 genes had an incidence rate>1%. FLT3 was the most frequently seen, which accounted for 44.9%, and 20.8% of the 178 patients present with FLT3-ITD. Conclusions: Patients aged 20-59 years are the most common group with newly diagnosed APL. No obvious difference was found in the ratio of males to females. In terms of risk stratification, patients divided into low and intermediate risk predominate. t (15;17) with additional chromosomal abnormalities accounted for 21% of 715 patients, in which +8 was most commonly seen. The long-form subtype was most frequently seen in PML-RARα-positive patients, and FLT3 was most commonly seen in the mutation spectrum of APL.
Collapse
Affiliation(s)
- M Z Yang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - L Li
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - H Wei
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - B C Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - K Q Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - D P Li
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - L Zhang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - R C Yang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y C Mi
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - J X Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| |
Collapse
|
3
|
Zhang GJ, Gong XY, Qiu SW, Zhou CL, Liu KQ, Lin D, Liu BC, Wei H, Wei SN, Li Y, Gu RX, Gong BF, Liu YT, Fang QY, Mi YC, Wang Y, Wang JX. [Dasatinib combined with multi-agent chemotherapy regimen in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a prospective study from a single center]. Zhonghua Xue Ye Xue Za Zhi 2021; 42:109-115. [PMID: 33858040 PMCID: PMC8071668 DOI: 10.3760/cma.j.issn.0253-2727.2021.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
目的 评价达沙替尼联合多药化疗方案在Ph染色体阳性急性淋巴细胞白血病(Ph+ ALL)患者中的疗效及安全性。 方法 前瞻性、单臂、开放的临床研究。2016年1月至2018年4月中国医学科学院血液病医院收治的30例初诊成人Ph+ ALL患者入组。采用多药化疗方案,标准诱导化疗为期4周,自诱导化疗第8天开始口服达沙替尼(商品名依尼舒,正大天晴药业集团股份有限公司产品)100 mg/d,持续应用至整体治疗结束。有条件和意愿进行移植者,可进行异基因造血干细胞移植或自体造血干细胞移植。 结果 所有30例患者在诱导治疗4周后均达到血液学完全缓解(HCR),累积完全分子学反应(MCR)率为70.0%(21/30)。中位随访时间为37.8(32.0~46.6)个月。3年总生存(OS)率为68.1%,3年无血液学复发生存(HRFS)率为61.6%。63.3%的患者在治疗3个月时达到主要分子学反应(MMR)(其中有43.3%患者达到MCR)。6个月时60.0%的患者达到MCR,达到MCR的患者具有更好的OS(P=0.004)、HRFS(P=0.049)和EFS(P=0.001)。15例(50.0%)患者在第1次HCR期内进行移植,移植组患者HRFS(P=0.030)和EFS(P=0.010)优于化疗组。 结论 达沙替尼联合多药化疗方案治疗初诊Ph+ALL安全有效。 临床试验注册 ClinicalTrials.gov,NCT02523976。
Collapse
Affiliation(s)
- G J Zhang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - X Y Gong
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - S W Qiu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - C L Zhou
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - K Q Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - D Lin
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - B C Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - H Wei
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - S N Wei
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y Li
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - R X Gu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - B F Gong
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y T Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Q Y Fang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y C Mi
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - J X Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| |
Collapse
|
4
|
Abstract
Objective: To systematically review the relationship between dietary patterns and human immunity and health. Methods: Chinese and English search terms, including "dietary pattern", "dietary structure", "nutrients", "food", "protein", "fat", "vitamins", "dietary fiber", "immunity", "inflammatory", "inflammation", "oxidative stress", were searched for relevant articles in PubMed, Web of Science, Wanfang and National Knowledge Infrastructure (CNKI) database from the collection start date to January 10, 2020. Results: A total of 1 Chinese article and 22 English articles were included, including 9 cross-sectional studies, 7 intervention studies, 6 cohort studies and 1 nested case-control study. Common evaluation methods for dietary patterns included dietary inflammatory index (DII), inflammatory score of the diet (ISD), empirical dietary inflammatory pattern (EDIP), dietary compliance score, and healthy eating index. There were 13 studies on Mediterranean dietary patterns and healthy dietary patterns with higher intake of vegetables, fruits, bean products, fish and dairy products in the included articles. The Mediterranean diet can reduce the levels of inflammatory markers such as CRP, IL-6, Hcy, WBC, and fibrinogen, as well as the levels of metabolic indicators such as vascular endothelial growth factor and endothelial function score, improve chronic inflammatory diseases and reduce the risk of chronic diseases. The higher the healthy diet score was, the lower the level of pro-inflammatory factors was. Even if the dietary recommendation was not met, the healthier the diet was, the lower the level of inflammatory factors was. Western dietary patterns were positively correlated with CRP, IL-6, E-selectin, sICAM-1, sVCAM-1 and other inflammatory factors, and can increase the incidence of type 2 diabetes and the risk of cardiovascular disease. However, one study did not found the relationship between them and hs-CRP. Conclusions: Dietary patterns are closely related to human immune function. Different dietary patterns have different inflammatory potentials according to the characteristics of food intake, which can directly or indirectly affect immune function.
Collapse
Affiliation(s)
- K Q Liu
- National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - X Y Ding
- National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - W H Zhao
- National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| |
Collapse
|
5
|
Abstract
Objective: To systematically review the effects of nutrients, food and diet patterns on markers of inflammation and oxidative stress. Methods: Nutrients, nutrition, food, diet, dietary structure, dietary patterns, protein, fat, vitamin, dietary fiber, inflammatory, inflammation, oxidative stress, immunity were used as search terms, and systematic retrieval of the literature in Wanfang Database, National Knowledge Infrastructure (CNKI), PubMed, Web of Science was carried out from the establishment of the database to January 10, 2020, and a systematic review of the literature meeting the requirements was conducted. Results: A total of 3 Chinese and 46 English articles were included. Literature showed that β-carotene, vitamin C, vitamin D, polyunsaturated fatty acids, some amino acids, dietary fiber, isoflavones, choline, betaine and resveratrol and other nutrients can reduce plasma inflammatory factors or oxidative stress marker levels, and nutrients such as cholesterol and trans fatty acids can increase their levels. Foods such as fish, lean meat, fruits, soybeans, cruciferous vegetables and nuts can reduce plasma inflammatory factors or oxidative stress marker levels, while foods such as milk and sugary beverages can increase plasma inflammatory factors or oxidative stress markers. Mediterranean dietary patterns and other healthy dietary patterns can reduce plasma levels of inflammatory factors or oxidative stress markers, while Western dietary patterns can increase their levels. Conclusion: Nutrients, food and dietary patterns can influence levels of plasma inflammatory factors or oxidative stress markers.
Collapse
Affiliation(s)
- X Y Ding
- National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - K Q Liu
- National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - W H Zhao
- National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| |
Collapse
|
6
|
Xu XQ, Ding XY, Liu KQ, Zhao WH. [Influence of nutrients on human immunity]. Zhonghua Yi Xue Za Zhi 2020; 100:3720-3726. [PMID: 33342151 DOI: 10.3760/cma.j.cn112137-20200728-02232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To systematically review the studies on impact of macronutrients and micronutrients on human's immunity including cell-meditated immunity and humoral immunity as well as disease outcome. Methods: The database searched included Wan Fang Data, China National Knowledge Infrastructure, PubMed and Web of Science. "Nutrients" , "food" , "diet structure" , "diet pattern" , "protein" , "fat" , "vitamin" , "mineral" etc. were searched in Chinese and English for nutrition related terms, and "inflammation" , "inflammatory" , "oxidative stress" , "immune" , "immunity" etc. were searched for immunity related terms in Chinese and English respectively for published articles till Jan. 10th, 2020. Results: A total of 53 articles including 18 Chinese articles and 35 English articles were included in this review. Studies mainly focused on the relationship between nutrients such as iron, zinc, vitamin A, vitamin D, vitamin E and fatty acids and immunity. In a summary, insufficiency or deficiency of nutrients would impact immunity of humans which was mostly reflected in changes of CD3(+), CD4(+), CD4(+)/CD8(+), IgA and IgG levels. Furthermore, nutrient intake level or serum level was associated with disease outcomes such as prevalence, occurring risk or severity of symptoms. Interventions studies on n-3 polyunsaturated fatty acid (n-3 PUFA), zinc and vitamin A confirmed the positive effects of such nutrients on immunity and disease outcome. Conclusions: The intake level or serum level of nutrients is associated with cell-meditated immunity and humoral immunity. Optimal status of nutrients plays an important role in effectively strengthening immune system and disease defense of humans.
Collapse
Affiliation(s)
- X Q Xu
- National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China; Zhongguancun Science Park, Haidianyuan Post-doc Work Station-Nestle R&D China Branch, Beijing 100016, China
| | - X Y Ding
- National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - K Q Liu
- National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - W H Zhao
- National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| |
Collapse
|
7
|
Li Y, Gong XY, Zhao XL, Wei H, Wang Y, Lin D, Zhou CL, Liu BC, Wang HJ, Li CW, Li QH, Gong BF, Liu YT, Wei SN, Zhang GJ, Mi YC, Wang JX, Liu KQ. [Rituximab combined with short-course and intensive regimen for Burkitt leukemia: efficacy and safety analysis]. Zhonghua Xue Ye Xue Za Zhi 2020; 41:502-505. [PMID: 32654465 PMCID: PMC7378285 DOI: 10.3760/cma.j.issn.0253-2727.2020.06.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
目的 探讨利妥昔单抗联合短疗程、高强度方案治疗成人Burkitt白血病患者的疗效和安全性。 方法 收集2006年1月30日至2018年9月12日中国医学科学院血液病医院收治的11例Burkitt白血病患者病例资料,分析统计患者的临床特征、完全缓解(CR)率、总生存率、无复发生存率及不良事件。 结果 11例患者中位年龄34(15~54)岁,其中男6例,女5例。发病时中位WBC 12.28(2.21~48.46)×109/L,HGB 113(74~147)g/L,PLT 35(13~172)×109/L,乳酸脱氢酶2 721(803~17 370)U/L,外周血中位原始细胞比例0.40(0.03~0.76),骨髓中位原始细胞比例0.840(0.295~0.945)。10例患者接受利妥昔单抗联合短疗程、高强度化疗,其中2例患者巩固化疗后行自体造血干细胞移植。所有治疗患者1个疗程CR率为100%,4年总生存率为90%,4年无复发生存率为90%。所有治疗患者中,只有1例患者在诱导化疗中出现肿瘤溶解综合征,经血液透析等治疗后肾功能恢复。无治疗相关性死亡病例。 结论 利妥昔单抗联合短疗程、高强度方案治疗成人Burkitt白血病疗效及安全性均较为理想。
Collapse
Affiliation(s)
- Y Li
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - X Y Gong
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - X L Zhao
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - H Wei
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - Y Wang
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - D Lin
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - C L Zhou
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - B C Liu
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - H J Wang
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - C W Li
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - Q H Li
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - B F Gong
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - Y T Liu
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - S N Wei
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - G J Zhang
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - Y C Mi
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - J X Wang
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - K Q Liu
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| |
Collapse
|
8
|
Liu KQ, Wang Y, Zhao Z, Lin D, Zhou CL, Liu BC, Gong XY, Zhao XL, Wei SN, Zhang GJ, Gong BF, Li Y, Liu YT, Mi YC, Wang JX, Wei H. [A single-center, randomized controlled trial of PEG-rhG-CSF and common rhG-CSF to promote neutrophil recovery after induction chemotherapy in newly diagnosed acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi 2019; 40:497-501. [PMID: 31340623 PMCID: PMC7342402 DOI: 10.3760/cma.j.issn.0253-2727.2019.06.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
目的 比较初诊急性髓系白血病(AML)患者诱导化疗后骨髓抑制期应用聚乙二醇化重组人G-CSF(PEG-rhG-CSF)与普通重组人G-CSF(rhG-CSF)促进中性粒细胞或白细胞恢复的时间。同时比较两种药物对患者感染发生率、住院时间的影响。 方法 采用前瞻性随机对照研究方法,将2014年8月至2017年12月间符合入组条件的初诊AML患者诱导治疗后按1∶1比例随机分成两组:PEG-rhG-CSF组和rhG-CSF组。对比分析两组患者中性粒细胞计数(ANC)或WBC恢复时间、感染发生率和住院时间。 结果 共入组初诊AML患者60例,PEG-rhG-CSF组30例,rhG-CSF组30例。两组患者除性别构成外,在年龄、化疗方案、化疗前ANC、WBC、诱导化疗疗效方面差异均无统计学意义(P值均>0.05)。PEG-rhG-CSF组患者与rhG-CSF组患者的ANC、WBC恢复中位时间分别为19(14~35)d、19(15~26)d,差异无统计学意义(t=0.580,P=0.566)。PEG-rhG-CSF组、rhG-CSF组患者骨髓抑制期感染的发生率分别为90.0%、93.3%,差异无统计学意义(P=1.000)。两组患者的中位住院时间分别为20.5(17~49)d、21(19~43)d,差异无统计学意义(P=0.530)。 结论 AML患者诱导治疗后应用PEG-rhG-CSF与rhG-CSF无论在ANC或WBC恢复时间,还是在感染的发生率及住院时间均相当。
Collapse
Affiliation(s)
- K Q Liu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Liu KQ, Wei H, Lin D, Wang Y, Zhou CL, Liu BC, Li XL, Zhao Y, Li HJ, Wang CW, Li QH, Li BF, Gong YT, Liu XY, Gong YC, Mi JX, Wang J. [Clinical significance of minimal residual disease in patients with Ph-negative precursor B-acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi 2019; 39:724-728. [PMID: 30369181 PMCID: PMC7342254 DOI: 10.3760/cma.j.issn.0253-2727.2018.09.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
目的 探讨微小残留病(MRD)水平在Ph染色体阴性的急性B淋巴细胞白血病(Ph− B-ALL)中的预后意义。 方法 采用多色流式细胞术对2010年9月至2017年11月初诊的193例Ph− B-ALL患者在治疗后1、3、6个月进行骨髓MRD监测,并对不同MRD水平患者的预后进行比较。 结果 中位随访22(1~92)个月,所有193例患者共行497次MRD检测。1个月时MRD水平<0.1%和≥0.1%患者的3年预期无复发生存(RFS)率分别为74.5%和29.9%,3年预期总生存(OS)率分别为67.5%和30.3%;3个月时MRD水平阴性和阳性患者的3年预期RFS率分别为75.6%和29.7%,3年预期OS率分别为71.6%和27.8%;6个月时MRD水平阴性或阳性患者的3年预期RFS率分别为74.6%和11.6%,3年预期OS率分别为74.0%和15.7%,差异均有统计学意义(P值均<0.001)。3个监测点全部达到MRD阴性标准的患者与至少1次未达到MRD阴性标准的患者比较,3年预期RFS、OS率差异均有统计学意义(80.5%对30.5%,77.1%对29.4%,P值均<0.001)。多因素分析结果显示,3个月时的MRD水平是Ph− B-ALL患者独立的预后因素之一。 结论 治疗后MRD监测对Ph− B-ALL的预后判断有重要意义。
Collapse
Affiliation(s)
- K Q Liu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Gu RX, Wei H, Wang Y, Liu BC, Zhou CL, Lin D, Liu KQ, Wei SN, Gong BF, Zhang GJ, Liu YT, Zhao XL, Gong XY, Li Y, Qiu SW, Mi YC, Wang JX. [Impact of duration of antibiotic therapy on the prognosis of patients with acute myeloid leukemia who had Gram-negative bloodstream infection in consolidation chemotherapy]. Zhonghua Xue Ye Xue Za Zhi 2019; 39:471-475. [PMID: 30032562 PMCID: PMC7342929 DOI: 10.3760/cma.j.issn.0253-2727.2018.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
目的 分析巩固化疗期间伴发革兰阴性菌(G−菌)血流感染的急性髓系白血病(AML)患者抗感染疗程对感染转归的影响。 方法 回顾性分析2010年9月至2016年1月入组“依据危险度分层对急性髓系白血病优化治疗的研究”临床试验的591例AML(非急性早幼粒细胞白血病)患者的血流感染资料,将其中巩固化疗期间发生G−菌血流感染且持续发热时间<7 d的114例次血流感染(89例患者)纳入研究,分析抗感染疗程对感染转归的影响。 结果 114例次血流感染发生时,患者中位ANC为0(0~5.62)×109/L,中性粒细胞缺乏(粒缺)持续的中位时间为9(3~26)d,抗感染治疗的中位时间为7(4~14)d。抗感染疗程≤7 d与>7 d组比较,停药后3 d内再发热比例、再次发生相同菌株血流感染比例分别为1.2%对3.0%、18.5%对21.2%,差异均无统计学意义(P=0.522,OR=0.400,95%CI 0.024~6.591;P=0.741,OR=0.844,95%CI 0.309~2.307)。同时,两组患者均未发生7 d及30 d内感染相关死亡。且倾向性评分平衡患者特征及用药差异因素后,抗感染疗程≤7 d较>7 d组再次发生相同菌株血流感染比例仍无明显增高(P=0.525,OR=0.663,95%CI 0.187~2.352)。 结论 对于巩固化疗期间伴发G−菌血流感染的AML患者,若发热时间<7 d,敏感抗菌药物治疗7 d后停药并不增加停药后3 d内再发热,粒缺期再次出现相同菌株血流感染及感染相关7 d、30 d内死亡风险。提示短疗程抗感染方案可以成为巩固化疗伴发G−菌血流感染AML患者感染控制情况下合理的治疗选择。
Collapse
Affiliation(s)
- R X Gu
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Xu MZ, Fang QY, Gong XY, Feng J, Jia YJ, Li QH, Liu KQ, Zhao XL, Ru K, Tian Z, Tang KJ, Wang M, Wang JX, Mi YC. [Screening of adult Ph-like acute lymphoblastic leukemia by multiplex real-time quantitative PCR]. Zhonghua Xue Ye Xue Za Zhi 2019; 38:956-961. [PMID: 29224319 PMCID: PMC7342795 DOI: 10.3760/cma.j.issn.0253-2727.2017.11.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Abstract
目的 探讨多重实时荧光定量PCR法早期、快速筛查Ph样急性淋巴细胞白血病(ALL)的可行性,了解Ph样ALL的临床特征及预后。 方法 2010年10月至2016年3月收治的118例初诊成人B-ALL患者纳入研究,利用多重实时荧光定量PCR法检测其中58例BCR-ABL融合基因和MLL重排均阴性患者Ph样相关融合基因及细胞因子受体样因子2(CRLF2)表达情况。比较分析Ph样融合基因阳性和(或)CRLF2高表达患者的临床特征、疗效和预后。 结果 检出Ph样融合基因阳性患者9例(9/58,15.5%),CRLF2高表达患者10例(10/58,17.2%)。Ph样融合基因阳性和(或)CRLF2高表达组、Ph阳性组、MLL重排阳性组以及其他患者组在年龄、WBC、免疫分型、细胞遗传学、危险度分组方面差异有统计学意义(P值均<0.01)。四组患者的2年总生存率分别为65%、47%、64%、74%(P=0.043),2年无复发生存率分别为51%、39%、62%、70%(P=0.010)。 结论 采用多重实时荧光定量PCR法筛查Ph样ALL患者可行,Ph样ALL患者预后较差。
Collapse
Affiliation(s)
- M Z Xu
- Institute of Hematology&Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Liu W, Xue F, Liu XF, Jiang EL, Yang DL, Liu KQ, Xiao ZJ, Zhang FK, Feng SZ, Han MZ, Zhang L, Yang RC. [Analysis of clinical efficacy of recombinant activated factor Ⅶ on bleeding in patients with hematologic disorders]. Zhonghua Xue Ye Xue Za Zhi 2018; 38:410-414. [PMID: 28565741 PMCID: PMC7354194 DOI: 10.3760/cma.j.issn.0253-2727.2017.05.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
目的 研究重组人凝血因子Ⅶa(rFⅦa)治疗血液病患者出血的疗效。 方法 回顾性分析rFⅦa治疗31例血液病患者共38次出血的临床资料。 结果 rFⅦa治疗获得性血友病A(AHA)/血友病伴抑制物、急性早幼粒细胞白血病(APL)、急性非APL白血病患者出血的总体有效率分别为90%(9/10)、71.4%(5/7)、60.0%(3/5),高于造血干细胞移植后患者(30.8%);rFⅦa治疗评分为2分出血的有效率(100.0%)高于3分(66.7%)及4分(51.6%)出血;5例次颅内出血中2例次(25.0%)有效;9例次血尿中6例次(66.7%)有效;12例次消化道出血中5例次(41.7%)有效。3例次关节及肌肉出血的疗效均为极好,5例次出血部位为皮肤、鼻黏膜、咽部及齿龈,疗效均为极好;移植后患者在出血评分为4分时,高剂量以及多次使用rFⅦa并不一定能取得好的疗效。AHA/血友病伴抑制物及急性白血病患者合并的出血,在评分为4分时,使用低剂量rFⅦa能取得好的疗效,但最低用药剂量(22.5 µg/kg)的疗效差。 结论 rFⅦa的止血疗效受疾病类型、出血部位以及严重程度等多个因素的影响。rFⅦa对AHA/血友病伴抑制物以及急性白血病患者的出血具有较好的疗效,但对移植后患者的出血疗效欠佳。出血早期使用rFⅦa对于疗效至关重要。在止血治疗的同时,应积极治疗基础疾病。
Collapse
Affiliation(s)
- W Liu
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Gong BF, Liu YT, Zhang GJ, Wei SN, Li Y, Liu KQ, Gong XY, Zhao XL, Qiu SW, Gu RX, Lin D, Wei H, Zhou CL, Liu BC, Wang Y, Mi YC, Wang JX. [Primary antifungal prophylaxis with posaconazole plays a pivotal role during chemotherapy of acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi 2018; 38:528-531. [PMID: 28655098 PMCID: PMC7342978 DOI: 10.3760/cma.j.issn.0253-2727.2017.06.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To evaluate the incidence of invasive fungal infections (IFI) and usage of intravenous antifungal drugs during remission induction chemotherapy in patients with acute myeloid leukemia (AML) under primary antifungal prophylaxis with posaconazole. Methods: Clinical records from newly diagnosed AML patients above 15 years old in one single center from February 2014 to January 2016 were retrospectively reviewed and analyzed, excluding acute promyelocytic leukemia. The incidence of IFI and usage of intravenous antifungal drugs were investigated between control group (not receiving any broad spectrum antifungal prophylaxis) and treatment group (receiving posaconazole as primary prophylaxis). Results: A total of 147 newly diagnosed AML patients were enrolled. Of them, 81 received prophylaxis with posaconazole, and 66 did not receive broad-spectrum antifungal treatment. 7 IFI occurred in posaconazole group, and all were possible cases; 19 IFI occurred in control group (3 proven, 4 probable, 12 possible). The incidence of IFI was significantly lower in treatment group than that in control group (8.6% vs 28.8%, χ(2)=10.138, P=0.001). Usage of intravenous antifungal drugs was significantly decreased in posaconazole group (18.5% vs 50.0%, χ(2)=16.390, P<0.001). Conclusion: Prophylaxis with posaconazole coulf prevent IFI and reduce usage of intravenous antifungal drugs significantly during remission induction chemotherapy in AML patients.
Collapse
Affiliation(s)
- B F Gong
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Wu WJ, Liu KQ, Li BJ, Dong C, Zhang ZK, Li PH, Huang RH, Wei W, Chen J, Liu HL. Identification of an (AC)n microsatellite in the Six1 gene promoter and its effect on production traits in Pietrain × Duroc × Landrace × Yorkshire pigs. J Anim Sci 2018; 96:17-26. [PMID: 29432614 DOI: 10.1093/jas/skx024] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2017] [Accepted: 02/05/2018] [Indexed: 12/22/2022] Open
Abstract
The Sine oculis homeobox 1 (Six1) gene is important for skeletal muscle growth and fiber specification; therefore, it is considered as a promising candidate gene that may influence porcine growth and meat quality traits. Nevertheless, the association of Six1 with these processes and the mechanisms regulating its expression remain unclear. The objectives of this study were to identify variant sites of Six1 in different pig breeds, conduct association analysis to evaluate the relationship between polymorphisms of these variants and porcine production traits in Pietrain × Duroc × Landrace × Yorkshire commercial pigs, and explore the potential regulatory mechanisms of Six1 affecting production traits. A total of 12 variants were identified, including 10 single- nucleotide variations (SNVs), 1 insertion- deletion (Indel), and 1 (AC)n microsatellite. Association analysis demonstrated that the SNV, g.1595A>G, was significantly associated with meat color (redness, a*); individuals with the G allele had greater a* values (P < 0.05). Moreover, our results demonstrated that the (AC)n polymorphism in the Six1 promoter was significantly associated with weaning weight (P < 0.05), carcass weight (P < 0.05), and thoracic and lumbar back fat (P < 0.01).In addition, we found that the (AC)n variant was closely related with Six1 expression levels and demonstrated this polymorphism on promoter activity by in vitro experiments. Overall, this study provides novel evidence for elucidating the effects of Six1 on porcine production traits as promising candidate and describes two variants with these traits, which are potential reference markers for pig molecular breeding. In addition, our data on the relationship between porcine Six1 expression and the polymorphic (AC)n microsatellite in its promoter may facilitate similar studies in other species.
Collapse
Affiliation(s)
- W J Wu
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Nanjing Agricultural University, Nanjing, China
| | - K Q Liu
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Nanjing Agricultural University, Nanjing, China
| | - B J Li
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Nanjing Agricultural University, Nanjing, China
| | - C Dong
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Nanjing Agricultural University, Nanjing, China
| | - Z K Zhang
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Nanjing Agricultural University, Nanjing, China
| | - P H Li
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Nanjing Agricultural University, Nanjing, China
| | - R H Huang
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Nanjing Agricultural University, Nanjing, China
| | - W Wei
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Nanjing Agricultural University, Nanjing, China
| | - J Chen
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Nanjing Agricultural University, Nanjing, China
| | - H L Liu
- Department of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, Nanjing Agricultural University, Nanjing, China
| |
Collapse
|
15
|
Feng J, Gong XY, Jia YJ, Liu KQ, Li Y, Dong XB, Fang QY, Ru K, Li QH, Wang HJ, Zhao XL, Jia YN, Song Y, Tian Z, Wang M, Tang KJ, Wang JX, Mi YC. [Spectrum of somatic mutations and their prognostic significance in adult patients with B cell acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi 2018; 39:98-104. [PMID: 29562441 PMCID: PMC7342576 DOI: 10.3760/cma.j.issn.0253-2727.2018.02.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/14/2017] [Indexed: 01/11/2023]
Abstract
Objective: To investigate the spectrum of gene mutations in adult patients with B-acute lymphoblastic leukemia (B-ALL), and to analyze the influences of different gene mutations on prognosis. Methods: DNA samples from 113 adult B-ALL patients who administered from June 2009 to September 2015 were collected. Target-specific next generation sequencing (NGS) approach was used to analyze the mutations of 112 genes (focused on the specific mutational hotspots) and all putative mutations were compared against multiple databases to calculate the frequency spectrum. The impact of gene mutation on the patients' overall survival (OS) and recurrence free survival (RFS) was analyzed by the putative mutations through Kaplan-Meier, and Cox regression methods. Results: Of the 113 patients, 103 (92.0%) harbored at least one mutation and 29 (25.6%) harbored more than 3 genes mutation. The five most frequently mutated genes in B-ALL are SF1, FAT1, MPL, PTPN11 and NRAS. Gene mutations are different between Ph+ B-ALL and Ph- B-ALL patients. Ph- B-ALL patients with JAK-STAT signal pathway related gene mutation, such as JAK1/JAK2 mutation showed a poor prognosis compared to the patients without mutation (OS: P=0.011, 0.001; RFS: P=0.014,<0.001). Patients with PTPN11 mutation showed better survival than those without mutation, but the difference was not statistically significant (P value > 0.05). Besides, in Ph+ B-ALL patients whose epigenetic modifications related signaling pathway genes were affected, they had a worse prognosis (OS: P=0.038; RFS: P=0.047). Conclusion: Gene mutations are common in adult ALL patients, a variety of signaling pathways are involved. The frequency and spectrum are varied in different types of B-ALL. JAK family gene mutation usually indicates poor prognosis. The co-occurrence of somatic mutations in adult B-ALL patients indicate the genetic complex and instability of adult B-ALL patients.
Collapse
Affiliation(s)
- J Feng
- State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Gong XY, Wang Y, Liu BC, Wei H, Li CW, Li QH, Zhao JW, Zhou CL, Lin D, Liu KQ, Wei SN, Gong BF, Zhang GJ, Liu YT, Zhao XL, Li Y, Gu RX, Qiu SW, Mi YC, Wang JX. [Characteristics and prognosis in adult acute myeloid leukemia patients with MLL gene rearrangements]. Zhonghua Xue Ye Xue Za Zhi 2018; 39:9-14. [PMID: 29551026 PMCID: PMC7343107 DOI: 10.3760/cma.j.issn.0253-2727.2018.01.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/12/2017] [Indexed: 01/27/2023]
Abstract
Objective: To analyze the clinical and laboratory characteristics, and prognosis of adult acute myeloid leukemia (AML) patients with MLL gene rearrangements. Methods: The medical records of 92 adult AML patients with MLL gene rearrangements from January 2010 to December 2016 were retrospectively analyzed. Results: 92 cases (6.5%) with MLL gene rearrangements were identified in 1 417 adult AML (Non-M(3)) patients, the median age of the patients was 35.5 years (15 to 64 years old) with an equal sex ratio, the median WBC were 21.00(0.42-404.76)×10(9)/L, and 78 patients (84.8%) were acute monoblastic leukemia according to FAB classification. Eleven common partner genes were detected in 32 patients, 9 cases (28.1%) were MLL/AF9(+), 5 cases (15.6%) were MLL/AF6(+), 5 cases (15.6%) were MLL/ELL(+), 2 cases (6.3%) were MLL/AF10(+), 1 case (3.1%) was MLL/SETP6(+), and the remaining 10 patients' partner genes weren't identified. Of 92 patients, 83 cases with a median follow-up of 10.3 (0.3-74.0) months were included for the prognosis analysis, the complete remission (CR) rate was 85.5% (71/83), the median overall survival (OS) and relapse free survival (RFS) were 15.4 and 13.1 months, respectively. Two-year OS and RFS were 36.6% and 29.5%, respectively. Of 31 patients underwent allogeneic hematopoietic stem-cell transplantation (allo-HSCT), two-year OS and RFS for patients received and non-received allo-HSCT were 57.9% and 21.4%, 52.7% and 14.9%, respectively (P<0.001). Among patients with partner genes tested, 9 of 32 cases (28.1%) were MLL/AF9(+), the median follow-up was 6.0(4.1-20.7) months. 3 patients with MLL/AF9 underwent allo-HSCT. 23 cases (71.9%) were non- MLL/AF9(+), the median follow-up was 7.8 (0.3-26.6) months. 14 patients (60.1%) with non-MLL/AF9 underwent allo-HSCT. One-year OS for patients with MLL/AF9 and non-MLL/AF9 were 38.1% and 55.5%, respectively (P=0.688). Multivariate analysis revealed that high WBC (RR=1.825, 95% CI 1.022-3.259, P=0.042), one cycle to achieve CR (RR=0.130, 95% CI 0.063-0.267, P<0.001), post-remission treatment with allo-HSCT (RR=0.169, 95% CI 0.079-0.362, P<0.001) were independent prognostic factors affecting OS. Conclusions: AML with MLL gene rearrangements was closely associated with monocytic differentiation, and MLL/AF9 was the most frequent partner gene. Conventional chemotherapy produced a high response rate, but likely to relapse, allo-HSCT may have the potential to further improve the prognosis of this group of patients.
Collapse
Affiliation(s)
- X Y Gong
- State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Peng N, Wei H, Lin D, Zhou CL, Liu BC, Wang Y, Liu KQ, Gong BF, Wei SN, Zhang GJ, Liu YT, Gong XY, Qiu SW, Mi YC, Wang JX. [Prognostic significance of flow cytometric minimal residual disease in acute myeloid leukemia during aplasia]. Zhonghua Xue Ye Xue Za Zhi 2017; 38:767-771. [PMID: 29081193 PMCID: PMC7348354 DOI: 10.3760/cma.j.issn.0253-2727.2017.09.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/14/2017] [Indexed: 11/16/2022]
Abstract
Objective: To investigate the impact of minimal residual disease (MRD) by multiparameter flow cytometry (MPFC) during aplasia on efficacy and prognosis of de novo acute myeloid leukemia (AML) (non M(3)) patients. Methods: The MRD data by 8-color MPFC during aplasia (day 14-15 of induction therapy) in 85 de novo AML (non M(3)) patients and the MRD impact on efficacy and prognosis were retrospectively analyzed. Results: Data of 85 patients, including 42 males (49.4%) and 43 females (50.6%) , were collected, with a median age of 35 (15-54) years. The median MRD by MPFC during aplasia was 0.58% (0-81.11%) , and 70 (82.4%) patients achieved complete remission (CR) after first induction chemotherapy. The cutoff of MRD by receiver operating characteristic (ROC) analysis was 2.305% (Se= 0.867, Sp=0.800) . The CR rate after one course was significantly higher in patients with MRD<2.305% [96.6% (56/58) ]than in patients with MRD≥2.305%[51.9% (14/27) ] (χ(2)=22.348, P<0.001) ; no significant difference with respect to relapse-free survival rate (χ(2)=1.08, P=0.299) or overall survival rate (χ(2)=0.42, P=0.516) could be demonstrated for the comparison of the two groups. Multivariates analysis showed MRD divided by 2.305% was the only independent prognostic factor for CR after one course (OR= 21.560, 95% CI 4.129-112.579, P<0.001) . Conclusion: Flow cytometric MRD divided by 2.305% during aplasia could be a predictor of efficacy after first induction therapy in AML patients.
Collapse
Affiliation(s)
- N Peng
- Institute of Hematology & Blood Disease Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Zhao N, Wei H, Wang Y, Lin D, Zhou CL, Liu BC, Liu KQ, Zhang GJ, Wei SN, Gong BF, Gong XY, Li W, Li Y, Liu YT, Qiu SW, Gu RX, Mi YC, Wang JX. [Prediction of outcome in acute myeloid leukemia by measurement of WT1 expression as a basic marker of minimal residual disease]. Zhonghua Xue Ye Xue Za Zhi 2017; 38:695-699. [PMID: 28954349 PMCID: PMC7348239 DOI: 10.3760/cma.j.issn.0253-2727.2017.08.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/27/2016] [Indexed: 11/14/2022]
Abstract
Objective: To probe the potential utility of Wilms tumor 1 (WT1) as a marker of minimal residual disease (MRD) in acute myeloid leukemia (AML) to estimate the relapse-predicting cut-off value. Methods: Quantitative assessment of bone marrow WT1 mRNA level was preformed using real-time quantitative reverse transcription polymerase chain reaction (RQ-RT-PCR) assay. The expression levels of WT1 dynamically measured with RQ-RT-PCR were retrospectively analyzed in 121 AML cases (not including acute promyelocytic leukemia) achieving complete remission (CR) after induction therapy followed by consolidation therapy. By comparing WT1 levels of patients with different post-therapy outcomes, the investigators used the receiver operating characteristic (ROC) curve to determine WT1 threshold so as to predict their clinical relapses. Then prognoses and the significance of intervention were analyzed between WT1 positive and negative patients according to the cut-off value of WT1. Results: According to ROC curve, WT1 level higher than 2.98% predicted the possibility of relapse. For simplicity and clinical application, 3.00% was used as the cut-off value of WT1 level for relapse. WT1 levels in 41 patients at diagnosis were detected, meanwhile 3 patients whose WT1 levels at diagnosis below 3.00% were excluded, then the median WT1 level of the rest 38 patients at diagnosis was 44.09% (range 7.19%-188.06%) . The median WT1 level in remission was 0.48% (352 samples, range 0-8.41%) . The median WT1 level at diagnosis was higher than that in remission. Excluding the 3 patients with WT1 level at diagnosis under 3.00%, the relapse rate of WT1 positive group (>3.00% during consolidation phase and follow-up) and WT1 negative group (≤3.00%) was 70.0% (14/20) and 12.2% (12/98) respectively (P<0.001) . The median time from WT1 positivity to clinical relapse was 58 days. Conclusions: WT1 expression level above 3.00% was associated with markedly high risk of relapse, which could be as a useful marker for monitoring MRD following consolidation therapy.
Collapse
Affiliation(s)
- N Zhao
- Institute of Hematology & Blood Disease Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Gong XY, Wang Y, Liu BC, Wei H, Zhou CL, Lin D, Liu KQ, Wei SN, Gong BF, Zhang GJ, Liu YT, Zhao XL, Li Y, Gu RX, Qiu SW, Mi YC, Wang JX. [Clinical features and prognosis in CD10(-) pre-B acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi 2017; 38:17-21. [PMID: 28219219 PMCID: PMC7348396 DOI: 10.3760/cma.j.issn.0253-2727.2017.01.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
目的 分析CD10阴性的前B急性淋巴细胞白血病(CD10−pre B-ALL)患者的临床特征和预后。 方法 对6例成人CD10− pre B-ALL患者的临床和实验室资料进行回顾性分析,结合文献复习明确该类型患者的临床特征及预后。 结果 CD10−pre B-ALL占ALL的1.5%(6/409),占B-ALL的1.8%(6/343),占pre B-ALL的11.5%(6/52)。6例患者均为男性,中位年龄为33.5岁,起病时中位WBC为101.78×109/L,所有患者均伴有MLL-AF4融合基因表达。5例患者经1个疗程诱导化疗即获得完全缓解(CR),1例患者经3个疗程化疗后才获得CR。2例患者在CR1期行异基因造血干细胞移植(allo-HSCT),1例患者CR后短期内即复发,在CR2期行allo-HSCT。1例患者正在等待移植。2例未移植患者1例复发死亡,1例尚处于缓解状态。 结论 CD10−pre B-ALL是一类具有独特临床特征的成人ALL亚型,发生率较低,常见于男性,起病时白细胞水平较高,MLL-AF4融合基因表达率高,常规化疗具有较高的缓解率,但易复发,allo-HSCT有可能改善其预后。
Collapse
Affiliation(s)
- X Y Gong
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Wang Y, Liu BC, Wei H, Lin D, Zhou CL, Liu KQ, Li W, Wei SN, Wang JY, Gong BF, Zhang GJ, Zhao XL, Liu YT, Gong XY, Li Y, Gu RX, Mi YC, Wang JX. [Homoharringtonine in newly diagnosed acute promyelocytic leukemia treatment: a prospective, randomized controlled trial]. Zhonghua Xue Ye Xue Za Zhi 2016; 37:183-8. [PMID: 27033753 PMCID: PMC7342959 DOI: 10.3760/cma.j.issn.0253-2727.2016.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/23/2015] [Indexed: 11/06/2022]
Abstract
OBJECTIVE To compare the efficacy and toxicities of combining homoharringtonine (HHT)±daunorubicin (DNR) with all-trans-retinoic acid (ATRA) based therapy and DNR plus ATRA based therapy in newly diagnosed low/intermediate risk acute promyelocytic leukemia (APL). METHODS A total of 96 newly diagnosed patients with APL were randomized to HHT group, DNR group and HHT+ DNR group prospectively. The complete remission (CR) rate, the overall survival (OS) and event-free survival (EFS) of three groups were analyzed. RESULTS There were 31 patients in HHT group, 33 patients in DNR group and 32 patients in HHT+ DNR group. The baseline characteristics of three groups were similar. No patient died during induction therapy. The morphologic CR rate was 100.0%. The median time to peak WBC counts in HHT+DNR group (4 days, range: 1-23 days) was significantly shorter than that in HHT group (9 days, range: 1-27 days) (P=0.008) and DNR group (7 days, range: 1-27 days) (P=0.240). There was no difference among three groups about the incidence of differentiation syndrome, the median interval to achieve CR, peak WBC counts and transfusions (P >0.05). All patients achieved complete molecular remission (CMR) during consolidation therapy. The interval to achieve CMR was no significantly difference among three groups (P >0.05). The 3-year OS rates for HHT group, DNR group and HHT+DNR group were 95.0%, 100.0% and 91.0%, respectively (P=0.595). The 3-year EFS rates for three groups were 93.0%, 90.0% and 85.0% (P=0.382). No difference was found in the incidence of adverse events among three groups (P >0.05). CONCLUSIONS Similar to DNR plus ATRA based therapy, HHT plus ATRA based induction and consolidation therapy should be one of highly-efficient treatment options for newly diagnosed APL. Clinical trial registration Chinese Clinical Trial Registry, ChiCTR-TRC-12002628.
Collapse
Affiliation(s)
- Y Wang
- Leukemia Center, Institute of Hematology & Blood Disease Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Liu Y, Pan L, Zhang ZN, Shi ZH, Wang Y, Jing ZC, Lee WY, Chan MC, Cheun TK, So KH, Yu CM, Lee WY, Pang TY, Kong WY, Chan KH, Kwok LM, Chan SW, Ko SSW, Tam CWY, Fok BSP, Hu M, Yin OQP, Chow MSS, Tomlinson B, Guo ZR, Wu M, Zhang LJ, Luo WS, Liu JC, Ding Y, Zhu QR, Chen Q, Chan SSW, Ahmad I, Graham CA, Rainer TH, Berdina ON, Madaeva IM, Dolgikh VV, Xie MX, Li YM, Gao X, Wang GY, Wang AL, Xu T, Tong WJ, Zhang YH, Pogodina AV, Dolgikh VV, Moretzkaya IS, Nawaz SK, Xu JB, Zhang YL, Liu Y, Huang G, Zhang TJ, Huang XB, Ou YLY, Chan SSW, Tse MM, Chan CPY, Graham CA, Rainer TH, Wong MCS, Yan B, Tam WWS, Wang HHX, Liu KSD, Liu KQ, Cheung CSK, Tong ELH, Sek ACH, John GK, Cheung NT, Yu CM, Leeder S, Griffiths S, Wang HHX, Wong MCS, Yan B, Tang JL, Wang JJ, Yu CM, Griffiths S, Wong MCS, Yan B, Tam WWS, Wang HHX, Liu KSD, Liu KQ, Cheung CSK, Tong ELH, Sek ACH, Cheung NT, Yu CM, Leeder S, Griffiths S, Shin SH, Woo SI, Kim DH, Park KS, Kwan J, Liu KQL, Wong MCS, Wang HHX, Liu KSD, Yan B, Yu CM, Griffiths S, Borumand H, Cheang IN, Law TC, Choi SKV, Chung LH, Chan SLD, Li YC, Choy PS, Hung YKS, Cheung YHK, Chan LH, Chan KHK. P077 * Evaluation of two-dimensional strain echocardiography in quantifying right ventricular function in patients with pulmonary hypertension. Eur Heart J Suppl 2012. [DOI: 10.1093/eurheartj/sur028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
22
|
Lee WY, Tam CS, Yan PY, Lam YY, Duchatelet S, Peat RA, Denjoy I, Itoh H, Berthet M, Crotti L, Ohno S, Pedrazzini M, Klug D, Schwartz PJ, Shimizu W, Horie M, Tregouet DA, Guicheney P, Tiong WN, Hwang SS, Fong AYY, Wee CC, Lai LYH, Tiong LL, Chang BC, Ong TK, Garg P, Ashraffi R, Chuah S, Baho H, Draz S, Mously F, Atta J, Kouatly A, Hussian A, Abu zeid H, Courtney A, Hamilton-Craig C, Strugnell W, Slaughter R, Luis CR, Habibian M, Luis SA, Raffel OC, Tung TH, Hsiung MC, Wei J, Clements IP, Hodge DO, Scott CG, Chai SC, Liew M, Leong G, Peng H, Ding J, Peng Y, Zhang Q, Xu Y, Chao X, Tian H, Zhang Y, Liu Y, Tong WJ, Liu YY, Wang J, Zhang YH, Wong MCS, Yan B, Tam WWS, Wang HHX, Liu KSD, Liu KQ, Cheung CSK, Tong ELH, Sek ACH, Cheung NT, Yu CM, Leeder S, Griffiths S, Poon KKC, Wong HL, Ng SH, Kwok WT, Yeung CL, Yu SY, Wan YP, Wan S, Underwood MJ, Chan PH, Alegria-Barrero E, Price S, Kelleher A, Moat N, Mario CD, Franzen O, Zhang YC, Lee AP, Lin QS, Fang F, Wan S, Underwood M, Yu CM, Mirhoseini SJ, Frouzannia SK, Mostafavi Pour Manshadi SMY, Naderi N, Sayegh S, Dandekar PG, Verma Y. A001 * Barriers of warfarin use for atrial fibrillation patients in Hong Kong. Eur Heart J Suppl 2012. [DOI: 10.1093/eurheartj/sur021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
23
|
Liu KQ, Bunnell SC, Gurniak CB, Berg LJ. T cell receptor-initiated calcium release is uncoupled from capacitative calcium entry in Itk-deficient T cells. J Exp Med 1998; 187:1721-7. [PMID: 9584150 PMCID: PMC2212298 DOI: 10.1084/jem.187.10.1721] [Citation(s) in RCA: 271] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/1998] [Indexed: 11/04/2022] Open
Abstract
Itk, a Tec family tyrosine kinase, plays an important but as yet undefined role in T cell receptor (TCR) signaling. Here we show that T cells from Itk-deficient mice have a TCR-proximal signaling defect, resulting in defective interleukin 2 secretion. Upon TCR stimulation, Itk-/- T cells release normal amounts of calcium from intracellular stores, but fail to open plasma membrane calcium channels. Since thapsigargin-induced store depletion triggers normal calcium entry in Itk-/- T cells, an impaired biochemical link between store depletion and channel opening is unlikely to be responsible for this defect. Biochemical studies indicate that TCR-induced inositol 1,4,5 tris-phosphate (IP3) generation and phospholipase C gamma1 tyrosine phosphorylation are substantially reduced in Itk-/- T cells. In contrast, TCR-zeta and ZAP-70 are phosphorylated normally, suggesting that Itk functions downstream of, or in parallel to, ZAP-70 to facilitate TCR-induced IP3 production. These findings support a model in which quantitative differences in cytosolic IP3 trigger distinct responses, and in which only high concentrations of IP3 trigger the influx of extracellular calcium.
Collapse
Affiliation(s)
- K Q Liu
- Program of Immunology, Division of Medical Sciences, Harvard University, Boston, Massachusetts 02115, USA
| | | | | | | |
Collapse
|
24
|
Abstract
TIA-1 and TIAR are two closely related RNA recognition motif (RRM) proteins which possess three RRM-type RNA binding domains (RRMs 1, 2, and 3). Although both proteins have been implicated as effectors of apoptotic cell death, the specific functions of TIA-1 and TIAR are not known. We have performed in vitro selection/amplification from pools of random RNA sequences to identify RNAs to which TIA-1 and TIAR bind with high affinity. Both proteins selected RNAs containing one or several short stretches of uridylate residues suggesting that the two proteins have similar RNA binding specificities. Replacement of the uridylate stretch with an equal number of cytidine residues eliminates the protein-RNA interaction. Mutational analysis indicates that, for both TIA-1 and TIAR, it is the second RNA binding domain (RRM 2) which mediates the specific binding to uridylate-rich RNAs. Although RRM 2 is both necessary and sufficient for this interaction, the affinity for the selected RNA (as determined by filter binding assays) does increase when the second domain of TIAR is expressed together with the first and third domains (Kd = 2 x 10(-8) M) rather than alone (Kd = 5 x 10(-8) M). Although RRM 3 (of either TIA-1 or TIAR) does not interact with the uridylate-rich sequences selected by the full-length proteins, it is a bona fide RNA binding domain capable of affinity-precipitating a population of cellular RNAs ranging in size from 0.5 to 5 kilobases. In contrast, RRM 1 does not affinity-precipitate cellular RNA. The inability of RRM 1 to interact with RNA may be due to the presence of negatively charged amino acids within the RNP 1 octamer.
Collapse
Affiliation(s)
- L M Dember
- Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
| | | | | | | |
Collapse
|
25
|
Hasty P, O'Neal WK, Liu KQ, Morris AP, Bebok Z, Shumyatsky GB, Jilling T, Sorscher EJ, Bradley A, Beaudet AL. Severe phenotype in mice with termination mutation in exon 2 of cystic fibrosis gene. Somat Cell Mol Genet 1995; 21:177-87. [PMID: 7482032 DOI: 10.1007/bf02254769] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Mice with a termination codon mutation in exon 2 of the cystic fibrosis (CF) gene were generated using homologous recombination in embryonic stem cells. Animals homozygous for the mutant allele display a severe intestinal phenotype similar to that previously reported for CF mutant mice. The null nature of this allele was demonstrated by the absence of detectable wild-type mRNA, by the absence of detectable CFTR in the serous gland collecting ducts of salivary tissues, and by the lack of cAMP-mediated short-circuit current responses in colonic epithelium of mutant animals.
Collapse
Affiliation(s)
- P Hasty
- Department of Biochemistry and Molecular Biology, University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Chen XJ, Liu TF, Liu KQ. Effects of lemakalim and thalium on early afterdepolarization in mouse atrial fibers. Methods Find Exp Clin Pharmacol 1992; 14:489-92. [PMID: 1287373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The effects of lemakalim (BRL 38227) and thallium ion (Tl) on action potential (AP) and on early afterdepolarization (EAD) were studied in mouse atrial fibers. Under treatment with lemakalim (25 mcM) or Tl (0.2 mM), the AP was not significantly changed except for the reduction of duration of AP (APD). EAD induced by 3.0 mM K superfusion was abolished by 50 mcM lemakalim and only partially inhibited or was not effected under 25 mcM lemakalim. However, EAD was abolished completely and rapidly by Tl treatment. With addition of K concentration in superfusate to 5.0 mM the EAD could only be partially inhibited. By further increasing the K concentration to 7.0 mM the EAD could be completely abolished. It is suggested that the activator of outward current could inhibit EAD as well as the blockers of inward currents.
Collapse
Affiliation(s)
- X J Chen
- Department of Biology, Peking University, Beijing, China
| | | | | |
Collapse
|
27
|
Dyer AR, Cutter GR, Liu KQ, Armstrong MA, Friedman GD, Hughes GH, Dolce JJ, Raczynski J, Burke G, Manolio T. Alcohol intake and blood pressure in young adults: the CARDIA Study. J Clin Epidemiol 1990; 43:1-13. [PMID: 1969463 DOI: 10.1016/0895-4356(90)90050-y] [Citation(s) in RCA: 108] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Associations between self-reported average daily alcohol intake and blood pressure were assessed in 5031 black and white men and women ages 18-30 from the Coronary Artery Risk Development in Young Adults Study (CARDIA). In general, intake was positively but weakly related to both systolic and diastolic blood pressure. Associations with systolic pressure were generally stronger than those with diastolic pressure. With average daily alcohol intake categorized as none, 0.1-9.9 ml, 10.0-19.9 ml, 20.0-29.9 ml, and 30.0+ ml, mean systolic pressure, adjusted for age, body mass index, education, smoking, and physical activity, increased progressively with increasing intake in black and white men and in white women. Mean diastolic pressure increased progressively with increasing intake only in white men and women, but was highest for those averaging 30.0+ ml per day in black women as well as white men and women. Mean pressures were also compared for those averaging 75.0+ ml per day (men) or 50.0+ ml per day (women) vs those reporting no intake. Differences in adjusted mean pressures for white men were 3.2 mmHg (95% confidence limits (CL) -0.3, 6.8) for systolic pressure and 1.7 mmHg (-1.6, 5.0) for diastolic pressure. In black men differences were 4.4 mmHg (1.4, 7.4) and 3.4 mmHg (0.6, 6.3), respectively. Differences in white women were 1.4 mmHg (-2.5, 5.3) for systolic pressure and 0.9 mmHg (-2.7, 4.5) for diastolic pressure and for black women, -0.2 mmHg (-4.3, 3.8) and 1.9 mmHg (-1.9, 5.8). Separate analyses in smokers and nonsmokers of the associations between alcohol intake and blood pressure suggested that associations may differ by smoking status in some sex-race groups.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- A R Dyer
- Department of Community Health and Preventive Medicine, Northwestern University Medical School, Chicago, Ill. 60614
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Wang ZM, Liu TF, Liu KQ. K+-free induced early afterdepolarization in cardiac ventricular fibers of guinea pig after cold treatment. Sci Sin B 1988; 31:1439-46. [PMID: 2855550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The genesis and elimination of early afterdepolarizations (EADs) have been investigated in guinea pig cardiac ventricular fibers after a short period of cooling (5 h, 2-4 degrees C). After rewarming them to 37 degrees C, EADs could be induced by K+-free superfusion at an appropriate driving stimulation (0.2 Hz) in all preparations. A high level plateau, which linearly increases its duration with time, appears ahead of EADs. The critical point of the plateau occurred steadily, at the level of -47 +/- 4 mV. Two types of triggered activity, all of which are the rhythmic activities in low level of membrane potential (-50 to -60 mV), appear on the plateau. There is no significant change after overdriving. Agonists of the Na-K pump (K+ and T1+) could stop the rhythmic activity immediately and turn the low level of membrane potential to high one. The results showed that high level plateau is the basis of genesis of EADs, and the activation of Na-K pump plays an important part in stopping triggered rhythms arising from EADs.
Collapse
Affiliation(s)
- Z M Wang
- Department of Biology, Peking University
| | | | | |
Collapse
|